+

US20020006956A1 - Propanolamine derivatives - Google Patents

Propanolamine derivatives Download PDF

Info

Publication number
US20020006956A1
US20020006956A1 US09/380,608 US38060899A US2002006956A1 US 20020006956 A1 US20020006956 A1 US 20020006956A1 US 38060899 A US38060899 A US 38060899A US 2002006956 A1 US2002006956 A1 US 2002006956A1
Authority
US
United States
Prior art keywords
compound
hydrogen
tetrahydro
alkoxy
benzocyclohepten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/380,608
Other versions
US6391915B2 (en
Inventor
Kiyoshi Taniguchi
Minoru Sakurai
Norio Hashimoto
Takumi Okamoto
Kazunori Tsubaki
Yasuyo Tomishima
Hisashi Takasugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of US20020006956A1 publication Critical patent/US20020006956A1/en
Assigned to FUJISAWA PHARMACEUTICAL CO., LTD. reassignment FUJISAWA PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HASHIMOTO, NORIO, OKAMOTO, TAKUMI, SAKURAI, MINORU, TAKASUGI, HISASHI, TANIGUCHI, KIYOSHI, TOMISHIMA, YASUYO, TSUBAKI, KAZUNORI
Application granted granted Critical
Publication of US6391915B2 publication Critical patent/US6391915B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to new propanolamine derivatives and salts thereof which are useful as a medicament.
  • This invention relates to new propanolamine derivatives and salts thereof.
  • new propanolamine derivatives and salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of gastrointestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to a method for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakisuria, urinary incontine
  • One object of this invention is to provide new and useful propanolamine derivatives and salts thereof which have gut selective sympathomimetic, anti-ulcerous, lipolytic and anti-pollakisuria activities.
  • Another object of this invention is to provide processes for the preparation of said propanolamine derivatives and salts thereof.
  • a further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said propanolamine derivatives and salts thereof.
  • Still further object of this invention is to provide a therapeutical method for the treatment and/or prevention of aforesaid diseases in human beings or animals, using said propanolamine derivatives and salts thereof.
  • R 1 is hydrogen or lower alkenyloxy
  • R 2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy
  • R 3 is hydrogen or N-protective group
  • n is an integer of 1 or 2
  • the object compound [I] or its salt can be prepared by the following processes.
  • R 1 , R 2 , R 3 and n are each as defined above, and R a 3 is N-protective group.
  • Suitable “lower alkenyl” moiety in the term “lower alkenyloxy” may include vinyl, 1-(or 2-)propenyl, 1-(or 2- or 3-)butenyl, 1-(or 2- or 3- or 4-)pentenyl, 1-(or 2- or 3- or 4- or 5-)hexenyl, methylvinyl, ethylvinyl, 1-(or 2- or 3-)-methyl-1-(or 2-)propenyl, 1-(or 2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)methyl-1-(or 2- or 3-)butenyl, and the like, in which preferable example may be C 2 -C 4 alkenyl, and more preferable example may be propenyl.
  • Suitable “lower alkoxy” moiety in the terms of “carboxy(lower)alkoxy” and “protected carboxy(lower)alkoxy” may be a straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy or the like, in which preferable one is C 1 -C 4 ones and more preferably methoxy.
  • Suitable “protected carboxy” moiety in the term “protected carboxy(lower)alkoxy” may include esterified carboxy and the like. And suitable example of said esterified carboxy may be substituted or unsubstituted lower alkoxycarbonyl [e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.], substituted or unsubstituted aryloxycarbonyl [e.g.
  • phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthyloxycarbonyl, etc.] substituted or unsubstituted ar(lower)alkoxycarbonyl e.g. benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, etc.
  • ar(lower)alkoxycarbonyl e.g. benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, etc.
  • N-Protective group may be common N-protective group such as acyl, for example, substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxycarbonyl [e.g. tert-butoxycarbonyl, tert-amyloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g.
  • acyl for example, substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxycarbonyl [e.g.
  • benzenesulfonyl, tosyl, etc.] nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.] or the like, in which preferable one is phenyl(lower)alkyl such as benzyl.
  • R 1 is hydrogen or lower alkenyloxy
  • R 2 is carboxy(lower)alkoxy or esterified carboxy(lower)alkoxy
  • R 3 is hydrogen or ar(lower)alkyl
  • n is an integer of 1 or 2.
  • R 1 is hydrogen or lower alkenyloxy
  • R 2 is lower alkoxycarbonyl(lower)alkoxy
  • R 3 is hydrogen or benzyl
  • n is an integer of 1 or 2 (more preferably an integer of 2).
  • Suitable salts of the object propanolamine derivatives [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.], an alkali metal salt [e.g. sodium salt, potassium salt, etc.] or the like.
  • an inorganic acid addition salt e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an organic acid addition salt e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benz
  • the object compound [I] or its salt can be prepared by reacting a compound [II] with a compound [III] or its salt.
  • Suitable salt of the compound [III] may be the same as those exemplified for the compound [I].
  • the reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.
  • a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.
  • the reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.
  • a conventional solvent such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.
  • reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • the object compound [Ib] or its salt can be prepared by subjecting a compound [Ia] or its salt to elimination reaction of the N-protective group.
  • Suitable salts of the compounds [Ia] and [Ib] may be the same as those exemplified for the compound [I].
  • This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like.
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, hydrazine, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.
  • an alkali metal e.g. sodium, potassium, etc.
  • an alkaline earth metal e.g. magnesium, calcium, etc.
  • the hydroxide or carbonate or bicarbonate thereof hydrazine
  • trialkylamine e.g. trimethylamine, triethylamine, etc.
  • picoline 1,5-diazabicyclo
  • Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.] and an acid addition salt compound [e.g. pyridine hydrochloride, etc.].
  • organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
  • an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.
  • an acid addition salt compound e.g. pyridine hydrochloride, etc.
  • trihaloacetic acid e.g. trichloroacetic acid, trifluoroacetic acid, etc.
  • cation trapping agents e.g. anisole, phenol, etc.
  • the reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, tetrachloromethane, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction.
  • a liquid base or acid can be also used as the solvent.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.
  • Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].
  • metal e.g. tin, zinc, iron, etc.
  • metallic compound e.g. chromium chloride, chromium acetate, etc.
  • organic or inorganic acid e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.
  • platinum catalysts e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
  • palladium catalysts e.g. spongy
  • the reduction is preferably carried out in the presence of a combination of palladium catalysts [e.g. palladium black, palladium on carbon, etc.] and formic acid or its salt [e.g. ammonium formate, etc.].
  • palladium catalysts e.g. palladium black, palladium on carbon, etc.
  • formic acid or its salt e.g. ammonium formate, etc.
  • the reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g. methanol, ethanol, propanol, etc.], chlorobenzene, N,N-dimethylformamide, or a mixture thereof.
  • a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc. or a mixture thereof.
  • reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating.
  • the compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary.
  • the compound [I] and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.
  • isomerization or rearrangement of the object compound [I] may occur due to the effect of the light, acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.
  • the object compound [I] and salts thereof possess gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, and are useful for the treatment and/or prevention of gastrointestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to methods for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakisuria, urinary incontinence or the like in case of nervous pollakisuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystit
  • the compound [I] and a salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid, semi-solid or liquid excipient suitable for oral, parenteral or external (topical) administration.
  • a pharmaceutically acceptable carrier such as an organic or inorganic solid, semi-solid or liquid excipient suitable for oral, parenteral or external (topical) administration.
  • the pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solutions, lotion, inhalant, ophthalmic preparations, suspension, emulsion, ointment, gel, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
  • the dosage of the compound [I] will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound [I] may be effective for treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
  • (2S)-1-[((6S)-3-Ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (190 mg) was treated with 4N hydrogen chloride in ethyl acetate to afford (2S)-1-[((6S)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol hydrochloride (103 mg).
  • the propanolamine derivatives and salts thereof of the object compound [I] including the object compounds of the above-mentioned Examples possess ⁇ 3 adrenergic receptor stimulating activity and are useful as ⁇ 3 adrenergic receptor agonists which are effective in the treatment and/or prevention of the aforesaid diseases.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to new propanolamine derivatives presented by the following formula [I]:
Figure US20020006956A1-20020117-C00001
wherein
R1 is hydrogen or lower alkenyloxy,
R2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy,
R3 is hydrogen or N-protective group,
n is an integer of 1 or 2,
and salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, to processes for the preparation thereof and to a pharmaceutical composition comprising the same.

Description

    TECHNICAL FIELD
  • This invention relates to new propanolamine derivatives and salts thereof which are useful as a medicament. [0001]
    • BACKGROUND ART
  • Some propanolamine derivatives having spasmolytic activity and relaxing activity on smooth muscle contraction have known as described, for example, in PCT International Publication WO94/25427. [0002]
    • DISCLOSURE OF INVENTION
  • This invention relates to new propanolamine derivatives and salts thereof. [0003]
  • More particularly, it relates to new propanolamine derivatives and salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of gastrointestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to a method for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakisuria, urinary incontinence or the like in case of nervous pollakisuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prostatitis or the like; and for the treatment and/or prevention of pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, melancholia, depression and the like. [0004]
  • One object of this invention is to provide new and useful propanolamine derivatives and salts thereof which have gut selective sympathomimetic, anti-ulcerous, lipolytic and anti-pollakisuria activities. [0005]
  • Another object of this invention is to provide processes for the preparation of said propanolamine derivatives and salts thereof. [0006]
  • A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said propanolamine derivatives and salts thereof. [0007]
  • Still further object of this invention is to provide a therapeutical method for the treatment and/or prevention of aforesaid diseases in human beings or animals, using said propanolamine derivatives and salts thereof. [0008]
  • The object propanolamine derivatives of this invention are new and can be represented by the following general formula [I]: [0009]
    Figure US20020006956A1-20020117-C00002
  • wherein [0010]
  • R[0011] 1 is hydrogen or lower alkenyloxy,
  • R[0012] 2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy,
  • R[0013] 3 is hydrogen or N-protective group,
  • n is an integer of 1 or 2, [0014]
  • and salts thereof (Hereinafter, these propanolamine derivatives may be mentioned as the object compound [I]). [0015]
  • The object compound [I] or its salt can be prepared by the following processes. [0016]
  • Process 1 [0017]
    Figure US20020006956A1-20020117-C00003
  • Process 2 [0018]
    Figure US20020006956A1-20020117-C00004
  • wherein [0019]
  • R[0020] 1, R2, R3 and n are each as defined above, and Ra 3 is N-protective group.
  • In the above and subsequent description of the present specification, suitable examples of the various definition to be included within the scope of the invention are explained in detail in the following. [0021]
  • The term “lower” is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided. [0022]
  • Suitable “lower alkenyl” moiety in the term “lower alkenyloxy” may include vinyl, 1-(or 2-)propenyl, 1-(or 2- or 3-)butenyl, 1-(or 2- or 3- or 4-)pentenyl, 1-(or 2- or 3- or 4- or 5-)hexenyl, methylvinyl, ethylvinyl, 1-(or 2- or 3-)-methyl-1-(or 2-)propenyl, 1-(or 2- or 3-)ethyl-1-(or 2-)propenyl, 1-(or 2- or 3- or 4-)methyl-1-(or 2- or 3-)butenyl, and the like, in which preferable example may be C[0023] 2-C4 alkenyl, and more preferable example may be propenyl.
  • Suitable “lower alkoxy” moiety in the terms of “carboxy(lower)alkoxy” and “protected carboxy(lower)alkoxy” may be a straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy or the like, in which preferable one is C[0024] 1-C4 ones and more preferably methoxy.
  • Suitable “protected carboxy” moiety in the term “protected carboxy(lower)alkoxy” may include esterified carboxy and the like. And suitable example of said esterified carboxy may be substituted or unsubstituted lower alkoxycarbonyl [e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, hexyloxycarbonyl, 2-iodoethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, etc.], substituted or unsubstituted aryloxycarbonyl [e.g. phenoxycarbonyl, 4-nitrophenoxycarbonyl, 2-naphthyloxycarbonyl, etc.], substituted or unsubstituted ar(lower)alkoxycarbonyl [e.g. benzyloxycarbonyl, phenethyloxycarbonyl, benzhydryloxycarbonyl, 4-nitrobenzyloxycarbonyl, etc.] and the like, in which preferable one is lower alkoxycarbonyl. [0025]
  • “N-Protective group” may be common N-protective group such as acyl, for example, substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxycarbonyl [e.g. tert-butoxycarbonyl, tert-amyloxycarbonyl, etc.], substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.] or the like, in which preferable one is phenyl(lower)alkyl such as benzyl. [0026]
  • Preferred embodiments of the object compound [I] are as follows: [0027]
  • R[0028] 1 is hydrogen or lower alkenyloxy,
  • R[0029] 2 is carboxy(lower)alkoxy or esterified carboxy(lower)alkoxy,
  • R[0030] 3 is hydrogen or ar(lower)alkyl, and
  • n is an integer of 1 or 2. [0031]
  • More preferred embodiments of the object compound [I] are as follows: [0032]
  • R[0033] 1 is hydrogen or lower alkenyloxy,
  • R[0034] 2 is lower alkoxycarbonyl(lower)alkoxy,
  • R[0035] 3 is hydrogen or benzyl, and
  • n is an integer of 1 or 2 (more preferably an integer of 2). [0036]
  • Suitable salts of the object propanolamine derivatives [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.], an alkali metal salt [e.g. sodium salt, potassium salt, etc.] or the like. [0037]
  • The processes for preparing the object compound [I] are explained in detail in the following. [0038]
  • Process 1 [0039]
  • The object compound [I] or its salt can be prepared by reacting a compound [II] with a compound [III] or its salt. [0040]
  • Suitable salt of the compound [III] may be the same as those exemplified for the compound [I]. [0041]
  • The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like. [0042]
  • The reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction. [0043]
  • The reaction temperature is not critical, and the reaction can be carried out under cooling to heating. [0044]
  • Process 2 [0045]
  • The object compound [Ib] or its salt can be prepared by subjecting a compound [Ia] or its salt to elimination reaction of the N-protective group. [0046]
  • Suitable salts of the compounds [Ia] and [Ib] may be the same as those exemplified for the compound [I]. [0047]
  • This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction or the like. [0048]
  • The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid. [0049]
  • Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, hydrazine, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like. [0050]
  • Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, hydrogen fluoride, etc.] and an acid addition salt compound [e.g. pyridine hydrochloride, etc.]. [0051]
  • The elimination using trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.]. [0052]
  • The reaction is usually carried out in a solvent such as water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, chloroform, tetrachloromethane, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. [0053]
  • The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction. [0054]
  • Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.]. [0055]
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like. [0056]
  • In case that the N-protective group is benzyl, the reduction is preferably carried out in the presence of a combination of palladium catalysts [e.g. palladium black, palladium on carbon, etc.] and formic acid or its salt [e.g. ammonium formate, etc.]. [0057]
  • The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g. methanol, ethanol, propanol, etc.], chlorobenzene, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc. or a mixture thereof. [0058]
  • The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to heating. [0059]
  • The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary. [0060]
  • It is to be noted that the compound [I] and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention. [0061]
  • It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to the effect of the light, acid, base or the like, and the compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention. [0062]
  • It is also to be noted that the solvating form of the compound [I] (e.g. hydrate, etc.) and any form of the crystal of the compound [I] are included within the scope of the present invention. [0063]
  • The object compound [I] and salts thereof possess gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-pollakisuria activities, and are useful for the treatment and/or prevention of gastrointestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly to methods for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakisuria, urinary incontinence or the like in case of nervous pollakisuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic prostatitis or the like; and for the treatment and/or prevention of pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, melancholia, depression and the like. [0064]
  • In order to illustrate the usefulness of the object compound [I], the pharmacological data of the object compound [I] are shown in the following. [0065]
  • Test 1 [0066]
  • Effect on isolated rat distal colon: [0067]
  • (1) Test Method [0068]
  • Male SD rats (180-230 g) were used. Animals were fasted for 24 hours prior to experiment. Distal colon was removed immediately after sacrifice and placed in an organ bath containing 25 ml Tyrode solution aerating with 95% O[0069] 2, 5% CO2 at 37° C. The strip was mounted under 0.5 g tension and spontaneous contractions were recorded isometrically. After the mobility was of a uniform size, test compound was added to an organ bath and the contractions were observed over a 30 minutes period. Effect of test compound was calculated by comparing contractions before and after test compound.
    (2) Test Result:
    Test Compound
    (Example No.) IC50 (M)
    1 4.2 × 10−9
  • Test 2 [0070]
  • Effect on isolated non-pregnant rat uterus: [0071]
  • (1) Test Method [0072]
  • Female SD rats (150-180 g) were used. 48 and 24 hours prior to use, rats were given estradiol (ovahormon benzoat: Trademark, Teikoku Hormone Mfg. Co., Ltd.) subcutaneously at a dose of 40 μg/rat to induce oestrus. The animals were killed and uteri were removed. Each strip was placed in an organ bath containing 25 ml Locke solution aerating with 95% O[0073] 2, 5% CO2 at 37° C. under 1 g tension. Contractions were recorded isometrically. After the spontaneous contractions were of a uniform size, test compound was added to organ bath. The motility was observed over a 20 minutes period. Effect of test compound was calculated by comparing contractions before and after test compound.
    (2) Test Result:
    Test Compound
    (Example No.) IC50 (M)
    1 3.7 × 10−7
  • For therapeutic purpose, the compound [I] and a salt thereof of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid, semi-solid or liquid excipient suitable for oral, parenteral or external (topical) administration. The pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solutions, lotion, inhalant, ophthalmic preparations, suspension, emulsion, ointment, gel, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives. [0074]
  • While the dosage of the compound [I] will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound [I] may be effective for treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day. [0075]
  • The following Preparations and Examples are given for the purpose of illustrating this invention. [0076]
    • Preparation 1
  • A suspension of (2S)-3-phenoxy-1,2-epoxypropane (300 mg) (IL FARMACO, 50 (10), 643 (1995)), N-benzyl-(1-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amine (535 mg), and ytterbium(III) trifluoromethanesulfonate (372 mg) in dichloromethane (15 ml) was stirred at room temperature for 3 days and partitioned between ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, washed with brine, dried over sodium sulfate, and evaporated in vacuo. The residue was chromatographed (dichloromethane-methanol) over silica gel (16 g) to afford (2S)-1-[N-benzyl-(6,7,8,9-tetrahydro-1-hydroxy-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (747 mg) as a colorless oil. [0077]
  • IR (KBr): 3359, 1244 cm[0078] −1
  • NMR (CDCl[0079] 3, δ): 1.15-1.35 (1H, m), 1.55-2.4 (5H, m), 2.55-3.35 (6H, m), 3.64-3.98 (4H, m), 4.85 (1H, br), 6.58 (1H, d, J=8.0 Hz), 6.75 (1H, d, J=7.4 Hz), 6.82-6.99 (4H, m), 7.15-7.31 (8H, m)
  • (+) APCI MS m/z: 418 (M[0080] ++1)
  • Preparation 2 [0081]
  • The following compound was obtained according to a similar manner to that of Preparation 1. [0082]
    • (2S)-1-[N-Benzyl-(6,7,8,9-tetrahydro-2-hydroxy-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol
  • IR (KBr): 3386, 1244 cm[0083] −1
  • NMR (CDCl[0084] 3, δ): 1.2-2.3 (5H, m), 2.45-3.07 (6H, m), 3.64-4.11 (5H, m), 4.0 (1H, br), 6.51-6.60 (2H, m), 6.82-7.01 (4H, m), 7.21-7.30 (8H, m)
  • (+) APCI MS m/z: 418 (M[0085] ++1)
    •  EXAMPLE 1
  • A suspension of 60% sodium hydride (54 mg, washed with n-hexane) in N,N-dimethylformamide (1 ml) was added slowly to a stirred solution of (2S)-1-[N-benzyl-(6,7,8,9-tetrahydro-1-hydroxy-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (512 mg) in N,N-dimethylformamide (5 ml) under ice cooling and the resulting mixture was stirred at the same temperature for 30 minutes. A solution of ethyl bromoacetate (225 mg) in N,N-dimethylformamide (1 ml) was added dropwise therein at the same temperature and the mixture was stirred at the same temperature for 4 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The extract was washed twice with brine, dried over magnesium sulfate, and evaporated in vacuo to afford (2S)-1-[N-benzyl-(1-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (0.59 g) as a crude oil. [0086]
  • IR (Film): 3450, 1759, 1734, 1246 cm[0087] −1
  • NMR (CDCl[0088] 3, δ): 1.22-1.33 (4H, m), 1.45-2.4 (5H, m), 2.5-3.15 (5H, m), 3.45 (1H, m), 3.64-3.95 (4H, m), 4.25 (2H, q, J=7.1 Hz), 4.58 (2H, s), 6.60 (1H, d, J=8.2 Hz), 6.81-7.08 (5H, m), 7.21-7.31 (7H, m)
  • (+) APCI MS m/z: 504 (M[0089] ++1)
    • EXAMPLE 2
  • The following compound was obtained according to a similar manner to that of Example 1. [0090]
    • (2S)-1-[N-Benzyl-(2-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol
  • IR (Film): 3437, 1759, 1738, 1246 cm[0091] −1
  • NMR (CDCl[0092] 3, δ): 1.22-1.45 (4H, m), 1.5-2.25 (4H, m), 2.5-3.05 (7H, m), 3.35 (1H, br), 3.70-3.95 (4H, m), 4.27 (2H, q, J=7.1 Hz), 4.57 and 4.58 (2H, s), 6.58-6.66 (2H, m), 6.83-7.07 (4H, m), 7.21-7.30 (7H, m)
  • (+) APCI MS m/z: 504 (M[0093] ++1)
    • EXAMPLE 3
  • To a mixture of N-((R)-1-phenylethyl)-((6R) -3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine hydrochloride (2.23 g) in dichloromethane and water was added 1N sodium hydroxide (5.5 ml), and the mixture was stirred for 30 minutes. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo to give the free amine. Under nitrogen, to a solution of the free amine and (2R)-3-phenoxy-1,2-epoxypropane (0.34 g) in dichloromethane (22 ml) was added ytterbium(III) trifluoromethanesulfonate (0.34 g) at 5°, and the mixture was stirred at room temperature for 1.5 days. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed (hexane-ethyl acetate) over silica gel to afford (2R)-1-[N-((R)-1-phenylethyl)-((6R) -3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amino]-3-phenoxy-2-propanol (2.07 g). [0094]
  • IR (Neat): 3444, 2929, 1758, 1496, 1245, 1166, 1041, 755 cm[0095] −1
  • NMR (CHCl[0096] 3, δ): 1.30 (3H, t, J=7.1 Hz), 1.45 (2H, d, J=6.9 Hz), 1.75-2.10 (3H, m), 2.27 (1H, d, J=12.3 Hz), 2.50-2.85 (4H, m), 3.01 (1H, dd, J=3.5, 13.8 Hz), 3.95-4.05 (4H, m), 4.28 (2H, q, J=7.1 Hz), 4.56 (2H, s), 6.29 (1H, d, J=2.6 Hz), 6.56 (1H, dd, J=2.7, 8.2 Hz), 6.86-7.01 (4H, m), 7.23-7.43 (7H, m)
    • EXAMPLE 4
  • To a mixture of N-((S)-1-phenylethyl)-((6S) -3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine hydrochloride (8.1 g) in dichloromethane and water was added 1N sodium hydroxide (20 ml), and the mixture was stirred for 20 minutes. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo to give the free amine. Under nitrogen, to a solution of the free amine and (2S)-3-phenoxy-1,2-epoxypropane (3.9 g) in dichloromethane (120 ml) was added tin(IV) chloride (1M in dichloromethane, 30 ml) dropwise at −20˜−10° C., and the solution was stirred at the same temperature for 1.5 hours. The resulting mixture was poured into 1N hydrogen chloride and extracted with dichloromethane. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo. The residue was chromatographed (hexane-ethyl acetate) over silica gel to give a less polor diastereomer (2S)-1-[N-((S)-1-phenylethyl) -((6S)-3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amino]-3-phenoxy-2-propanol (6.65 g) and a more polor diastereomer (2R)-1-[N-((S)-1-phenylethyl) -((6S)-3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amino]-3-phenoxy-2-propanol (228 mg). less polor diastereomer: [0097]
  • IR (Neat): 1758, 1496, 1243, 1195, 1043, 755 cm[0098] −1
  • NMR (CHCl[0099] 3, δ): 1.29 (3H, t, J=7.1 Hz), 1.45 (3H, d, J=6.9 Hz), 1.14-2.03 (4H, m), 2.27 (1H, d, J=12.6 Hz), 2.57-2.82 (5H, m), 3.01 (1H, dd, J=3.6, 13.9 Hz), 3.98-4.14 (4H, m), 4.29 (2H, q, J=7.1 Hz), 4.56 (2H, s), 6.29 (1H, d, J=2.7 Hz), 6.56 (1H, dd, J=2.7, 8.2 Hz), 6.89-6.99 (4H, m), 7.25-7.43 (7H, m)
  • (+) APCI MS (m/z): 518 (M[0100] ++1)
  • more polor diastereomer: [0101]
  • IR (Neat): 1758, 1496, 1243, 1195, 1041, 755 cm[0102] −1
  • NMR (CHCl[0103] 3, δ): 1.31 (3H, t, J=7.1 Hz), 1.42 (3H, d, J=6.8 Hz), 1.40-2.19 (4H, m), 2.46-2.99 (7H, m), 3.72-3.83 (1H, m), 3.89-4.15 (4H, m), 4.28 (2H, q, J=7.1 Hz), 4.56 (2H, s), 6.47 (1H, d, J=2.7 Hz), 6.59 (1H, dd, J=2.7, 8.2 Hz), 6.86-7.00 (4H, m), 7.19-7.38 (7H, m)
  • (+) APCI MS (m/z): 518 (M[0104] ++1)
    • EXAMPLE 5
  • The following compound was obtained according to a similar manner to that of Example 4. [0105]
    • (2S)-1-[N-((R)-1-Phenylethyl)-((6R)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol
  • IR (Neat): 3500, 2929, 1760, 1585, 1500, 1245, 1041, 755 cm[0106] −1
  • NMR (CHCl[0107] 3, δ): 1.31 (3H, t, J=7.1 Hz), 1.42 (2H, d, J=6.8 Hz), 1.45-2.19 (4H, m), 2.46-3.00 (7H, m), 3.74-3.87 (1H, m), 3.93-4.12 (3H, m), 4.28 (2H, d, J=7.1 Hz), 4.56 (2H, s), 6.47 (1H, d, J=2.6 Hz), 6.59 (1H, dd, J=2.7, 8.2 Hz), 6.86-7.00 (4H, m), 7.21-7.38 (7H, m)
  • (+) APCI MS (m/z): 518 (M+1) [0108]
    • Preparation 3
  • Under nitrogen, to the solution of 5-methoxy-1-tetralone (25 g) in dichloromethane (125 ml) were added zinc(II) iodide (0.91 g) and trimethylsilyl nitrile (27 ml) at room temperature, and stirred at the same temperature for 12 hours. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, water and brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo to afford 6-methoxy-1-(trimethylsilanyloxy)-1,2,3,4-tetrahydronaphthalene -1-carbonitrile (41.3 g). [0109]
  • IR (Neat): 2954, 1587, 1467, 1261, 1031, 844 cm[0110] −1
  • NMR (CHCl[0111] 3, δ): 0.02 (9H, s), 1.68-2.18 (4H, m), 2.49 (3H, t, J=6.3 Hz), 3.62 (3H, s), 6.57-7.17 (2H, m)
    • Preparation 4
  • Under nitrogen, to the slurry of lithium aluminum hydride (11.4 g) in tetrahydrofuran (200 ml) was added 6-methoxy -1-(trimethylsilanyloxy)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile (41.3 g) in tetrahydrofuran (200 ml) dropwise at 5° C., and the mixture was stirred at the same temperature for 1 hour and at room temperature for 2 hours. To the mixture were added sodium fluoride (12.6 g) and water (16.2 ml) at 5° C., and the mixture was vigorously stirred at room temperature for 30 minutes. The precipitate was removed by filtration and the filter cake was washed with ethyl acetate-ethanol (95:5). The filtrate was evaporated in vacuo to afford 1-aminomethyl-5-methoxy -1,2,3,4-tetrahydronaphthalen-1-ol (28.6 g). [0112]
  • NMR (CHCl[0113] 3, δ): 1.64-2.12 (4H, m), 2.55-2.82 (2H, m), 2.85 (2H, s), 3.84 (3H, s), 6.76 (1H, dd, J=1.8, 7.3 Hz), 7.05-7.34 (2H, m)
    • Preparation 5
  • To a solution of 1-aminomethyl-5-methoxy-1,2,3,4-tetrahydronaphthalen -1-ol (26.6 g) in 1,4-dioxane (60 ml), acetic acid (24 ml) and water (210 ml) was added sodium nitrite (9.7 g) in water (60 ml) dropwise at 5° C., and the mixture was stirred at the same temperature for 2.5 hours. The resulting mixture was diluted with ethyl acetate and separated. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was chromatographed (hexane-ethyl acetate) over silica gel to afford 1-methoxy-5,7,8,9-tetrahydro-6H-benzocyclohepten-6-one (12.7 g). [0114]
  • NMR (CHCl[0115] 3, δ): 1.84-2.04 (2H, m), 2.52 (2H, t, J=7.0 Hz), 2.97-3.04 (2H, m), 3.70 (2H, s), 3.81 (3H, s), 6.76 (1H, d, J=7.7 Hz), 6.81 (1H, d, J=8.4 Hz), 7.13 (1H, t, J=7.9 Hz)
  • (+) APCI MS (m/z): 191 (M[0116] ++1), 177
    • Preparation 6
  • A solution of 1-methoxy-5,7,8,9-tetrahydro-6H-benzocyclohepten -6-one (6.0 g) and benzylamine (3.4 ml) in toluene (60 ml) in the presence of a catalytic amount of p-toluenesulfonic acid monohydrate was refluxed for 2 hours to remove water as the toluene azeotrope, and then the mixture was evaporated in vacuo. To the residue in methanol (60 ml) was added sodium borohydride (1.2 g) under nitrogen at 5° C., and the mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into ice-cold water and stirred for 30 minutes before adding ethyl acetate and brine. After separation, the organic layer was washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was chromatographed (hexane-ethyl acetate-methanol) over silica gel to afford N-benzyl-(1-methoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amine (7.27 g). [0117]
  • NMR (CHCl[0118] 3, δ): 1.32-1.57 (2H, m), 1.70-1.93 (2H, m), 1.95-2.15 (1H, m), 2.58-2.79 (2H, m), 2.88-3.18 (3H, m), 3.78 (3H, s), 3.78 (2H, d, J=13.0 Hz), 3.89 (1H, d, J=13.0 Hz), 6.74 (1H, d, J=8.2 Hz), 6.80 (1H, d, J=7.5 Hz), 7.07 (1H, t, J=7.8 Hz), 7.16-7.37 (5H, m)
  • (+) APCI MS (m/z): 282 (M[0119] ++1)
    • Preparation 7
  • Under nitrogen, N-benzyl-(1-methoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amine (4.5 g) in dichloromethane (45 ml) was added boron tribromide (1M in dichloromethane, 32 ml) dropwise at 0° C., and the mixture was stirred at the same temperature for 2 hours. The resulting mixture was poured into ice-cold water and the precipitate was collected by filtration. The filter cake was added to the mixture of water and ethyl acetate, and then adjusted to pH 9 with 1N sodium hydroxide. After separation, the organic layer was dried over anhydrous magnesium sulfate and evaporated in vacuo to afford N-benzyl-(1-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine (3.72 g). [0120]
  • NMR (CHCl[0121] 3, δ): 1.35-1.57 (1H, m), 1.68-2.13 (3H, m), 2.55-3.08 (5H, m), 3.79 (1H, d, J=12.8 Hz), 3.91 (1H, d, J=12.8 Hz), 6.59 (1H, dd, J=1.2, 7.9 Hz), 6.75 (1H, d, J=6.6 Hz), 6.93 (1H, t, J=7.7 Hz), 7.17-7.36 (5H, m)
  • (+) APCI MS (m/z): 268 (M[0122] ++1)
    • Preparation 8
  • A solution of 3-methoxy-5,7,8,9-tetrahydro-6H-benzocyclohepten -6-one (10 g) and (R)-1-phenylethylamine (6.8 ml) in toluene (80 ml) in the presence of a catalytic amount of p-toluenesulfonic acid monohydrate (0.10 g) was refluxed for 5 hours to remove water as the toluene azeotrope, and then the mixture was evaporated in vacuo. To the residue in methanol (80 ml) was added Raney nickel (NDT 90, 15 ml) and the mixture was stirred at room temperature in the presence of hydrogen at 3.2-4.0 kgf/cm[0123] 2 for 15 hours, and filtered. After evaporation in vacuo, the residue was dissolved in ethyl acetate (150 ml). To the solution was added 4N hydrogen chloride in ethyl acetate (26 ml) dropwise at 10-15° C. The mixture was stirred at 5° C. for 1 hour and allowed to stand overnight in a refrigerator. After the mixture was diluted by ether, the precipitate was collected and the filter cake was washed with ether and dried under reduced pressure to afford N-((R)-1-phenylethyl)-(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amine hydrochloride (13.7 g).
  • NMR (DMSO-d[0124] 6, δ): 0.90-1.19 (1H, m), 1.68 (3H, d, J=6.5 Hz), 1.70-2.10 (2H, m), 2.25-2.75 (4H, m), 2.90-3.33 (2H, m), 3.38-3.70 (3H, s), 4.50-4.95 (1H, m), 6.57-6.85 (2H, m), 6.92-7.05 (1H, m), 7.35-7.53 (3H, m), 7.70-7.88 (2H, m)
    • Preparation 9
  • To a mixture of N-((R)-1-phenylethyl)-(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amine hydrochloride (13.7 g) in a mixture of ethyl acetate and water was added 28% aqueous ammonium hydroxide (30 ml), and the mixture was stirred for 20 minutes. After separation, the organic layer was washed with brine (twice), dried over anhydrous magnesium sulfate and evaporated in vacuo. To a solution of the residue in 1-propanol (200 ml) was added L-tartaric acid (6.8 g), and the mixture was warmed to 95° C. to dissolve it. Then the solution was slowly cooled to room temperature, and stirred at 5° C. for 1 hour. The precipitate was collected, washed with a little amount of precooled 1-propanol and dried under reduced pressure to afford N-((R)-1-phenylethyl)-((6R)-3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine L-tartaric acid (9.47 g). [0125]
  • NMR (DMSO-d[0126] 6, δ): 0.97-1.25 (1H, m), 1.44 (2H, d, J=6.5 Hz), 1.65-1.95 (2H, m), 1.97-2.15 (1H, m), 2.23-2.37 (1H, m), 2.53-2.75 (1H, m), 2.75-2.95 (1H, m), 3.06 (1H, d, J=13.5 Hz), 3.70 (3H, s), 4.38-4.53 (1H, m), 6.61 (1H, dd, J=2.6, 8.2 Hz), 6.76 (1H, d, J=2.5 Hz), 6.94 (1H, d, J=8.2 Hz), 7.18-7.42 (3H, m), 7.55 (2H, d, J=6.9 Hz)
    • Preparation 10
  • A mixture of N-((R)-1-phenylethyl)-((6R)-3-methoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amine L-tartaric acid (9.47 g) in a mixture of ethyl acetate and water was adjusted to alkali with 28% aqueous ammonium hydoxide and separated. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated in vacuo. Under nitrogen, to the residue in dichloromethane (140 ml) was added boron tribromide (1M in dichloromethane, 42.5 ml) dropwise at −10˜0° C., and the mixture was stirred at the same temperature for 1 hour. The resulting mixture was poured into ice-cold water with stirring. After stirred at 5° C. for 2 hours, the precipitate was collected. The filter cake was washed with water and dried under reduced pressure to afford N-((R)-1-phenylethyl)-((6R)-3-hydroxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine hydrobromide (7.78 g). [0127]
  • NMR (DMSO-d[0128] 6, δ): 0.97-1.23 (1H, m), 1.27-2.01 (3H, m), 1.61 (2H, d, J=6.6 Hz), 2.05-2.65 (3H, m), 2.89 (1H, t, J=10.4 Hz), 3.12 (1H, d, J=13.7 Hz), 4.77-4.96 (1H, br s), 6.49 (1H, dd, J=2.4, 8.1 Hz), 6.66 (1H, d, J=2.4 Hz), 6.86 (1H, d, J=8.1 Hz), 7.37-7.59 (3H, m), 7.65 (2H, d, J=6.5 Hz), 8.74-8.96 (1H, br s), 9.17-9.50 (1H, br s)
  • (+) APCI MS (m/z): 282 (M[0129] ++1)
    • Preparation 11
  • A mixture of N-((R)-1-phenylethyl)-((6R)-3-hydroxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)aminehydrobromide (7.67 g), ethyl bromoacetate (3.8 ml), potassium carbonate (17.6 g), and tetrabutylammonium chloride (1.18 g) in a mixture of dichloromethane (80 ml) and water (40 ml) was refluxed for 9 hours. After separation, the organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The residue was dissolved in ethyl acetate (90 ml). To the solution was added 4N hydrogen chloride in ethyl acetate (5.6 ml), and the mixture was stirred at 5° C. for 1 hour. The precipitate was collected, washed with a little amount of ice-cold ethyl acetate, and dried under reduce pressure to afford N-((R)-1-phenylethyl) -((6R)-3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amine hydrochloride (4.99 g). [0130]
  • NMR (DMSO-d[0131] 6, δ): 0.95-1.42 (2H, m), 1.23 (3H, t, J=7.1 Hz), 1.46-2.05 (3H, m), 1.67 (3H, d, J=6.5 Hz), 2.26-2.77 (4H, m), 2.99 (1H, t, J=13.4 Hz), 3.13-3.35 (1H, m), 3.37 (2H, s), 4.20 (2H, q, J=7.1 Hz), 4.70 (2H, s), 4.73-4.95 (1H, m), 6.62 (1H, dd, J=2.6, 8.2 Hz), 6.85 (1H, d, J=2.6 Hz), 6.96 (1H, d, J=8.3 Hz), 7.32-7.48 (3H, m), 7.76 (2H, d, J=6.5 Hz), 9.17-9.39 (1H, m), 10.05-10.30 (1H, m)
  • (+) APCI MS (m/z): 368 (M[0132] ++1)
    • EXAMPLE 6
  • A solution of (2S)-3-phenoxy-1,2-epoxypropane (140 mg) and N-benzyl-(3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amine (240 mg) in ethanol (1.36 ml) was stirred under reflux for 2 days, cooled to room temperature, and poured into aqueous sodium bicarbonate solution. The mixture was extracted with ethyl acetate. The extract was washed with water and evaporated in vacuo. The residue was chromatographed (chloroform) over silica gel (10 g) and the eluate was treated with 4N-hydrogenchloride in ethyl acetate to afford (2S)-l-[N-benzyl-(3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol hydrochloride as a crude oil. [0133]
  • A mixture of the crude oil and 10% palladium on activated carbon (50% wet, 150 mg) in ethanol (10 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure and filtered. The filtrate was evaporated in vacuo and the residue was washed with ether to afford (2S)-1-[(3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol hydrochloride (182 mg) as a powder. [0134]
  • mp: 122-128° C. [0135]
  • IR (Nujol): 3340, 3190, 2800-2350, 1740, 1220 cm[0136] −1
  • NMR (DMSO-d[0137] 6, δ): 1.21 (3H, t, J=7.1 Hz, CH3), 1.7-2.8 (8H, m, 4CH2), 2.95-3.3 (3H, m, CH2NCH), 3.9-4.25 (5H, m, OCH2CHO, COOCH2), 4.75 (2H, s, OCH2COO), 5.9 (1H, br s, OH), 6.6-7.35 (8H, m, aromatic H), 8.65-9.2 (3H, m)
  • EI MS (m/z): 413 (M[0138] +), 276, 247, 206
  • Anal. Calcd. for C[0139] 24H31NO5.HCl.H2O: C, 61.59; H, 7.32; N, 2.99; Found: C, 61.70; H, 7.03; N, 2.97;
    • EXAMPLE 7
  • A solution of 3-(2-allyloxyphenoxy)-1,2-epoxypropane (144 mg) and (S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydro -2-naphthalenamine (obtained from the corresponding hydrochloride (200 mg) in a usual manner) in ethanol (5 ml) was stirred under reflux for 2 hours, cooled to room temperature, and evaporated in vacuo. The residue was chromatographed (ethyl acetate) over silica gel (6.0 g) to afford an oil, which was converted to the oxalate using oxalic acid (35.3 mg) in a usual manner to afford 3-(2-allyloxyphenoxy) -1-[((2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalen -2-yl)amino]-2-propanol oxalate (182 mg) as a powder. [0140]
  • mp: 105-109° C. [0141]
  • IR (KBr): 3325, 3190, 2800-2350, 1736 cm[0142] −1
  • NMR (DMSO-d[0143] 6, δ): 1.21 (3H, t, J=7.1 Hz, CH3), 1.74 (1H, m, CH2), 2.21 (1H, m, CH2), 2.78 (3H, m, CH2), 3.10-3.24 (3H, m, CH2), 3.42 (1H, m, NCH), 3.9-4.05 (3H, m, OCH2CHO), 4.16 (2H, q, J=7.1 Hz, COOCH2), 4.58 (2H, d, J=5.1 Hz, OCH2C═), 4.72 (2H, s, OCH2COO), 5.25 (1H, dd, J=17.4, 1.8 Hz, ═CH2), 5.42 (1H, dd, J=17.4, 1.8 Hz, ═CH2), 5.6 (1H, br, OH), 5.96-6.14 (1H, m, CH═), 6.65-6.75 (2H, m, aromatic H), 6.88-7.05 (5H, m, aromatic H)
  • EI MS (m/z): 455 (M[0144] +), 262
    • EXAMPLE 8
  • A mixture of (2S)-1-[N-benzyl-(1-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (0.55 g) and 10% Pd/C (50% wet, 150 mg) in methanol (6 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 4 hours and filtered. The filtrate was evaporated in vacuo and the residue was chromatographed (chloroform-ethanol) over silica gel (8 g) to afford (2S)-1-[(1-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (365 mg) as a pale yellow solid. The solid (109 mg) was treated with 4N hydrogen chloride in ethyl acetate and powdered from ether to afford (2S)-1-[(1-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amino]-3-phenoxy-2-propanol hydrochloride (96 mg) as a colorless amorphous powder. [0145]
  • mp: 43-58° C. [0146]
  • IR (KBr): 3384, 2800-2350, 1755, 1736, 1246, 1207 cm[0147] −1
  • NMR (DMSO-d[0148] 6, δ): 1.15-1.3 (1H, m), 1.21 (3H, t, J=7.1 Hz), 1.7-2.1 (2H, m), 2.25-2.42 (2H, m), 2.95-3.45 (6H, m), 4.01 (2H, m), 4.15 (2H, q, J=7.1 Hz), 4.22 (1H, m), 4.76 (2H, s), 5.9 (1H, d, J=4.8 Hz), 6.76-7.12 (6H, m), 7.31 (2H, t, J=7.8 Hz), 8.81 (1H, br), 9.12 (1H, br)
  • (+) APCI MS m/z: 414 (M[0149] ++1)
    • EXAMPLE 9
  • A mixture of (2S)-1-[N-benzyl-(2-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (362 mg) and 10% Pd/C (50% wet, 100 mg) in ethanol (4 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 5 hours and filtered. The filtrate was evaporated in vacuo and the residue was chromatographed (dichloromethane-ethanol) over silica gel (6 g) to afford (2S)-1-[(2-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (274 mg) as a pale yellow oil. The oil (95 mg) and oxalic acid (20 mg) were dissolved in ethanol and the solution was evaporated in vacuo. The residue was powdered from ether to afford (2S)-1-[(2-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol oxalate (1:1) (85 mg) as a colorless powder. [0150]
  • mp: 78.5-91.5° C. [0151]
  • IR (KBr): 3442, 3408, 2800-2350, 1753, 1641, 1599, 1241, 1213 cm[0152] −1
  • NMR (DMSO-d[0153] 6, δ): 1.21 (3H, t, J=7.1 Hz), 1.35 (1H, m), 1.8 (1H, m), 2.0 (1H, m), 2.25 (1H, m), 2.69 (2H, m), 2.95-3.25 (5H, m), 3.99 (2H, m), 4.16 (2H and 1H, q (J=7.1 Hz) and m, respectively), 4.72 (2H, s), 5.5 (1H, br), 6.65-6.75 (2H, m), 6.94-6.99 (3H, m), 7.08-7.14 (1H, m), 7.27-7.36 (2H, m)
  • (+) APCI MS (m/z): 414 (M[0154] ++1)
  • Anal. Calcd. for C[0155] 24H31NO5.C2H2O4.0.2H2O: C, 61.58; H, 6.63; N, 2.76; Found: C, 61.51; H, 6.61; N, 2.71;
    • EXAMPLE 10
  • A solution of (2S)-1-[(1-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (103 mg) in methanol (5.0 ml) and 0.1N sodium hydroxide aqueous solution (2.5 ml) was stirred for 22 hours and evaporated in vacuo. The residue was triturated in diethyl ether and the precipitated powder was collected by filtration to afford sodium [6,7,8,9-tetrahydro-6-[((2S) -2-hydroxy-3-phenoxypropyl)amino]-5H-benzocyclohepten-1-yloxy]acetate (98 mg) as a pale yellow powder. [0156]
  • mp: 65° C. (dec.) [0157]
  • IR (KBr): 3411, 1599, 1240 cm[0158] −1
  • NMR (DMSO-d[0159] 6, δ): 1.2-2.0 (4H, m), 2.45-2.85 (7H, m), 3.12 (1H, m), 3.75-3.95 (3H, m), 4.05 (2H, s), 5.02 (1H, br d), 6.57 (1H, d, J=8.2 Hz), 6.64 (1H, d, J=7.2 Hz), 6.85-6.94 (4H, m), 7.27 (2H, t, J=8.0 Hz)
  • (+) APCI MS m/z: 386 (M[0160] +−Na+2)
  • Anal. Calcd. for C[0161] 22H26NO5.H2O: C, 62.11; H, 6.63; N, 3.29; Found: C, 62.31; H, 6.59; N, 3.20;
    • EXAMPLE 11
  • The following compound was obtained according to a similar manner to that of Example 10. [0162]
    • Sodium [6,7,8,9-tetrahydro-6-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-5H-benzocyclohepten-2-yloxy]acetate
  • mp: 166-174° C. [0163]
  • IR (KBr): 3431, 1601, 1248 cm[0164] −1
  • NMR (DMSO-d[0165] 6, δ): 1.25-1.95 (4H, m), 2.35-2.85 (7H, m), 3.25 (1H, m), 3.75-4.15 (3H, m), 4.01 (2H, s), 4.99 (1H, br s), 6.48 (1H, dd, J=8.1, 2.5 Hz), 6.55 (1H, d, J=2.5 Hz), 6.87-6.96 (4H, m), 7.27 (2H, t, J=8.0 Hz)
  • (+) APCI MS m/z: 386 (M[0166] +−Na+2)
  • Anal. Calcd. for C[0167] 22H26NO5Na.1.4H2O: C, 61.07; H, 6.71; N, 3.24; Found: C, 61.10; H, 6.42; N, 3.14;
    • EXAMPLE 12
  • A mixtur3 of (2R)-1-[N-((R)-1-phenylethyl)-((6R)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (2.0 g) and 10% palladium on activated carbon (50% wet, 0.70 g) in ethanol (24 ml) and tetrahydrofuran (12 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 3.5 hours, and filtered. The filtrate was evaporated in vacuo. The residue was chromatographed (chloroform-methanol) over silica gel to afford (2R)-1-[((6R)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (1.37 g). [0168]
  • IR (KBr): 1760, 1498, 1249, 1033, 757 cm[0169] −1
  • NMR (CHCl[0170] 3, δ): 1.29 (3H, t, J=7.1 Hz), 1.42-1.67 (1H, m), 1.69-1.90 (2H, m), 1.94-2.13 (1H, m), 2.69-2.97 (7H, m), 3.94-4.05 (3H, m), 4.25 (2H, d, J=7.1 Hz), 4.56 (2H, s), 6.62 (1H, dd, J=2.7, 8.2 Hz), 6.85-7.03 (4H, m), 7.20-7.33 (2H, m)
  • (+) APCI MS (m/z): 414 (M[0171] ++1)
    • EXAMPLE 13
  • A mixture of (2S)-1-[N-((S)-1-phenylethyl)-((6S) -3-ethoxycarbonylmethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten -6-yl)amino]-3-phenoxy-2-propanol (0.65 g) and 10% palladium on activated carbon (50% wet, 0.20 g) in ethanol (6 ml) and tetrahydrofuran (3 ml) was stirred at room temperature in the presence of hydrogen at an atmospheric pressure for 1 hour, and filtered. The filtrate was evaporated in vacuo. The residue was chromatographed (chloroform-methanol) over silica gel to afford (2S)-1-[((6S)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (430 mg). (2S)-1-[((6S)-3-Ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (190 mg) was treated with 4N hydrogen chloride in ethyl acetate to afford (2S)-1-[((6S)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol hydrochloride (103 mg). [0172]
  • IR (KBr): 3417, 1754, 1598, 1502, 1245, 1203, 1076, 755 cm[0173] −1
  • NMR (DMSO-d[0174] 6, δ): 1.20 (3H, t, J=7.1 Hz), 1.17-1.40 (1H, m), 1.72-2.10 (2H, m), 2.19-2.35 (1H, m), 2.66-2.77 (2H, m), 2.98-3.45 (5H, m), 4.01 (2H, d, J=5.1 Hz), 4.16 (2H, q, J=7.1 Hz), 4.11-4.33 (1H, m), 4.71 (2H, s), 5.92 (1H, d, J=4.7 Hz), 6.64-6.73 (1H, m), 6.83 (1H, d, J=2.5 Hz), 6.93-7.08 (4H, m), 7.31 (2H, t, J=7.9 Hz), 8.70-9.15 (2H, m)
  • (+) APCI MS (m/z): 414 (M[0175] ++1)
    • EXAMPLE 14
  • To a solution of (2S)-1-[((6S)-3-ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy -2-propanol (249 mg) in ethanol (1 ml) was added 1N sodium hydroxide at 5° C. After stirred at room temperature for 2 hours, the mixture was evaporated in vacuo to afford sodium [(6S)-6-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-3-yloxy]acetate (210 mg). [0176]
  • IR (KBr): 3417, 1610, 1498, 1425, 1247, 1060, 754 cm[0177] −1
  • NMR (D[0178] 2O, δ): 1.35-1.58 (1H, m), 1.65-2.06 (3H, m), 2.59-2.93 (4H, m), 3.89-4.12 (3H, m), 4.41 (2H, s), 6.65 (1H, dd, J=2.6, 8.2 Hz), 6.80 (1H, d, J=2.6 Hz), 6.94-7.09 (5H, m), 7.30-7.42 (2H, m)
  • (+) APCI MS (m/z): 386 (M[0179] +−Na+2)
    • EXAMPLE 15
  • The following compounds were obtained according to a similar manner to that of Example 13. [0180]
  • (1) (2S)-1-[((6R)-3-Ethoxycarbonylmethoxy-6,7,8,9-tetrahydro -5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol hydrochloride [0181]
  • IR (KBr): 3446, 1749, 1504, 1243, 1207, 757 cm[0182] −1
  • NMR (DMSO-d[0183] 6, δ): 1.21 (3H, t, J=7.1 Hz), 1.16-1.38 (1H, m), 1.71-2.12 (2H, m), 2.23-2.37 (1H, m), 2.65-2.74 (2H, m), 2.98-3.16 (4H, m), 3.19-3.30 (1H, m), 4.00 (2H, d, J=5.1 Hz), 4.17 (2H, q, J=7.1 Hz), 4.13-4.32 (1H, m), 4.72 (2H, s), 5.91 (1H, d, J=4.8 Hz), 6.69 (1H, dd, J=2.6, 8.3 Hz), 6.81 (1H, d, J=2.6 Hz), 6.92-7.08 (4H, m), 7.25-7.37 (2H, m), 8.58-8.90 (1H, m), 8.91-9.25 (1H, m)
  • (+) APCI MS (m/z): 414 (M[0184] ++1)
  • (2) (2R)-1-[((6S)-3-Ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol hydrochloride [0185]
  • IR (KBr): 3446, 1749, 1498, 1243 cm[0186] −1
  • NMR (DMSO-d[0187] 6, δ): 1.21 (3H, t, J=7.1 Hz), 1.16-1.43 (1H, m), 1.70-2.13 (2H, m), 2.25-2.39 (1H, m), 2.63-2.75 (2H, m), 2.95-3.38 (5H, m), 4.00 (2H, d, J=5.1 Hz), 4.17 (2H, q, J=7.1 Hz), 4.08-4.32 (1H, m), 4.72 (2H, s), 5.91 (1H, d, J=4.7 Hz), 6.69 (1H, dd, J=2.6, 8.2 Hz), 6.82 (1H, d, J=2.6 Hz), 6.92-7.08 (4H, m), 7.25-7.17 (2H, m), 8.65-8.90 (1H, br s), 8.97-9.28 (1H, br s)
  • (+) APCI MS (m/z): 414 (M[0188] ++1)
    • EXAMPLE 16
  • The following compounds were obtained according to a similar manner to that of Example 14. [0189]
  • (1) Sodium [(6R)-6-[((2R)-2-hydroxy-3-phenoxypropyl)amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-3-yloxy]acetate [0190]
  • IR (KBr): 3421, 1602, 1498, 1247, 1060, 754 cm[0191] −1
  • NMR (D[0192] 2O, δ): 1.35-1.55 (1H, m), 1.63-2.05 (3H, m), 2.55-2.97 (7H, m), 3.89-4.13 (3H, m), 4.40 (2H, s), 6.64 (1H, dd, J=2.6, 8.2 Hz), 6.79 (1H, d, J=2.6 Hz), 6.90-7.09 (4H, m), 7.25-7.41 (2H, m)
  • MALDI-MS (m/z): 408 (M[0193] ++1), 386
  • (2) Sodium [(6S)-6-[((2R)-2-hydroxy-3-phenoxypropyl)amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-3-yloxy]acetate [0194]
  • IR (KBr): 3444, 1627, 1600, 1500, 1421, 1249, 1058, 752 cm[0195] −1
  • NMR (D[0196] 2O, δ): 0.94-1.17 (1H, m), 1.10-1.70 (3H, m), 2.19-2.65 (7H, m), 3.45-3.72 (3H, m), 3.97 (2H, s), 6.62 (1H, dd, J=2.6, 8.2 Hz), 6.39 (1H, d, J=2.5 Hz), 6.45-6.70 (4H, m), 6.85-6.99 (2H, m)
  • MALDI-MS (m/z): 386 (M[0197] ++1)
  • (3) Sodium [(6R)-6-[((2S)-2-hydroxy-3-phenoxypropyl)amino]-6,7,8,9-tetrahydro-5H-benzocyclohepten-3-yloxy]acetate [0198]
  • IR (KBr): 3444, 1600, 1498, 1253, 1245, 1047, 752 cm[0199] −1
  • NMR (D[0200] 2O, δ): 1.37-1.63 (1H, m), 1.66-2.09 (3H, m), 2.63-3.05 (7H, m), 3.94-4.17 (3H, m), 6.66 (1H, dd, J=2.5, 8.2 Hz), 6.82 (1H, d, J=2.5 Hz), 6.93-7.11 (4H, m), 7.31-7.43 (2H, m)
  • (+) APCI MS (m/z): 386 (M[0201] +−Na+2)
    • EXAMPLE 17
  • The following compound was obtained according to a similar manner to that of Example 12. [0202]
    • (2R)-1-[((6S)-3-Ethoxycarbonylmethoxy -6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)amino]-3-phenoxy-2-propanol (137 mg) was obtained.
  • NMR (CDCl[0203] 3, δ): 1.29 (3H, t, J=7.1 Hz), 1.45-1.68 (1H, m), 1.71-1.93 (2H, m), 1.95-2.13 (1H, m), 2.30-3.05 (7H, m), 3.94-4.08 (3H, m), 4.26 (2H, q, J=7.1 Hz), 4.58 (2H, s), 6.64 (1H, dd, J=2.7, 8.2 Hz), 6.76 (1H, d, J=2.7 Hz), 6.85-7.03 (4H, m), 7.21-7.33 (2H, m)
  • The propanolamine derivatives and salts thereof of the object compound [I] including the object compounds of the above-mentioned Examples possess β[0204] 3 adrenergic receptor stimulating activity and are useful as β3 adrenergic receptor agonists which are effective in the treatment and/or prevention of the aforesaid diseases.

Claims (8)

What we claim is:
1. A compound of the formula
Figure US20020006956A1-20020117-C00005
wherein
R1 is hydrogen or lower alkenyloxy,
R2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy,
R3 is hydrogen or n-protective group,
n is an integer of 1 or 2,
and salts thereof.
2. A compound of claim 1,
wherein
R1 is hydrogen or lower alkenyloxy,
R2 is carboxy(lower)alkoxy or lower alkoxycarbonyl(lower)alkoxy,
R3 is hydrogen or ar(lower)alkyl, and
n is an integer of 1 or 2.
3. A process for preparing a compound of the formula:
Figure US20020006956A1-20020117-C00006
wherein
R1 is hydrogen or lower alkenyloxy,
R2 is carboxy(lower)alkoxy or protected carboxy(lower)alkoxy,
R3 is hydrogen or N-protective group, and
n is an integer of 1 or 2, or salts thereof, which comprises
(a) reacting a compound of the formula:
Figure US20020006956A1-20020117-C00007
 with a compound of the formula:
Figure US20020006956A1-20020117-C00008
 or its salt to provide a compound of the formula:
Figure US20020006956A1-20020117-C00009
 or its salt, in the above formulas,
R1, R2, R3 and n are each as defined above, or
(b) subjecting a compound of the formula
Figure US20020006956A1-20020117-C00010
 or its salt to elimination reaction of the N-protective group to provide a compound of the formula:
Figure US20020006956A1-20020117-C00011
 or its salt, in the above formulas,
R1, R2 and n are each as defined above, and
Ra 3 is N-protective group.
4. A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salt thereof, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
5. A medicament comprising a compound of claim 1 or pharmaceutically acceptable salt thereof, as an active ingredient.
6. A compound of claim 1 or pharmaceutically acceptable salt thereof for use as a medicament.
7. Use of a compound of claim 1 or pharmaceutically acceptable salt thereof as β3 adrenergic receptor agonist.
8. A method for the treatment and/or prevention of spasm or hyperanakinesia; gastric ulcer, duodenal ulcer or peptic ulcer caused by non steroidal anti-inflammatory drugs; dysuria; or pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, metancholia or depression, which comprises administering
US09/380,608 1997-03-17 1998-03-17 Propanolamine derivatives Expired - Fee Related US6391915B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPO5659 1997-03-17
ATPO5659 1997-03-17
AUPO5659A AUPO565997A0 (en) 1997-03-17 1997-03-17 Propanolamine derivatives
PCT/JP1998/001112 WO1998041497A1 (en) 1997-03-17 1998-03-17 Propanolamine derivatives

Publications (2)

Publication Number Publication Date
US20020006956A1 true US20020006956A1 (en) 2002-01-17
US6391915B2 US6391915B2 (en) 2002-05-21

Family

ID=3799962

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/380,608 Expired - Fee Related US6391915B2 (en) 1997-03-17 1998-03-17 Propanolamine derivatives

Country Status (4)

Country Link
US (1) US6391915B2 (en)
EP (1) EP0976720A4 (en)
AU (1) AUPO565997A0 (en)
WO (1) WO1998041497A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037022A1 (en) * 2000-09-25 2004-02-26 Minoru Sakurai Aminoalcohol derivatives

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940484D1 (en) 1998-04-06 2009-04-09 Astellas Pharma Inc Use of beta-3 adrenergic receptor agonists in the treatment of dysuria
DE19845405C2 (en) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
FR2809725B1 (en) 2000-06-06 2004-05-07 Sanofi Synthelabo PROPANOLAMINOTETRALINS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2003035600A1 (en) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Process for producing benzocycloheptene derivative
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
MX355697B (en) 2010-04-12 2018-04-27 Supernus Pharmaceuticals Inc Methods for producing viloxazine salts and novel polymorphs thereof.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55124742A (en) * 1979-03-20 1980-09-26 Kyowa Hakko Kogyo Co Ltd Novel aminoalcohol derivative
FR2640969B1 (en) * 1988-12-23 1991-11-22 Midy Spa
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2643076B1 (en) * 1989-02-14 1991-06-21 Midy Spa CARBOXYALKYL-ETHERS OF 2-AMINO-7-HYDROXYTETRALINE
IT1241988B (en) * 1990-06-15 1994-02-02 Sigma Tau Ind Farmaceuti 2- AMMINOTETRALINE-6, 7-ACTIVE SUBSTITUTES AS IMMUNOMODULANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037022A1 (en) * 2000-09-25 2004-02-26 Minoru Sakurai Aminoalcohol derivatives
US6826033B2 (en) * 2000-09-25 2004-11-30 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives

Also Published As

Publication number Publication date
AUPO565997A0 (en) 1997-04-10
EP0976720A1 (en) 2000-02-02
US6391915B2 (en) 2002-05-21
EP0976720A4 (en) 2002-03-06
WO1998041497A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
EP0579833B1 (en) Ethanolamine derivatives with anti-pollakiuria activity
US5387710A (en) Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities
FR2757157A1 (en) INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
SK404191A3 (en) Indole derivatives, method of their production and pharmaceutical preparation with their contents
US5130339A (en) Phenylethanolaminomethyltetralins and pharmaceutical use
WO2001044227A1 (en) Phenoxypropanolamines, preparation and therapeutic use thereof
US6391915B2 (en) Propanolamine derivatives
US20020120148A1 (en) Propanolamine derivatives
US6353025B1 (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
US5296596A (en) Hexahydroazepine derivatives, a process for their preparation
US5488151A (en) {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts
KR950006891B1 (en) How to prepare amino alcohol
WO2001017989A2 (en) Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists
WO2000012462A1 (en) Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO1994025427A1 (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
US20030032834A1 (en) Aminoalcohol derivatives
US7030160B2 (en) Propanolaminotetralines, preparation thereof and compositions containing same
US4526891A (en) Substituted alkyl amine derivatives of 6,11-dihydro-11-oxodibenz[b,e]oxepins
RU2125983C1 (en) Ethanolamine derivatives, method of their synthesis, pharmaceutical composition, method of treatment
US20030181726A1 (en) Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
FR2688218A1 (en) Quaternary ammonium salts of aromatic amino compounds, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AS Assignment

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TANIGUCHI, KIYOSHI;SAKURAI, MINORU;HASHIMOTO, NORIO;AND OTHERS;REEL/FRAME:012560/0623

Effective date: 19990906

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060521

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载